NASDAQ:BIOC

Biocept Stock Forecast, Price & News

$4.35
-0.07 (-1.58 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.25
$4.43
50-Day Range
$4.03
$5.07
52-Week Range
$3.46
$13.00
Volume159,300 shs
Average Volume423,803 shs
Market Capitalization$58.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
30 days | 90 days | 365 days | Advanced Chart
Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.


Biocept logo

About Biocept

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.20 out of 5 stars

Medical Sector

961st out of 2,100 stocks

Medical Laboratories Industry

16th out of 40 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept
or view top-rated stocks.

What stocks does MarketBeat like better than Biocept?

Wall Street analysts have given Biocept a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biocept wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Biocept?

Biocept saw a drop in short interest in the month of May. As of May 28th, there was short interest totaling 593,500 shares, a drop of 23.9% from the May 13th total of 780,300 shares. Based on an average daily trading volume, of 358,900 shares, the short-interest ratio is presently 1.7 days.
View Biocept's Short Interest
.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Biocept
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings data on Wednesday, May, 12th. The medical research company reported $0.19 EPS for the quarter. The medical research company earned $17.76 million during the quarter. Biocept had a negative net margin of 15.69% and a negative trailing twelve-month return on equity of 28.05%.
View Biocept's earnings history
.

How has Biocept's stock been impacted by Coronavirus (COVID-19)?

Biocept's stock was trading at $3.7690 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BIOC stock has increased by 15.4% and is now trading at $4.35.
View which stocks have been most impacted by COVID-19
.

When did Biocept's stock split? How did Biocept's stock split work?

Biocept shares reverse split before market open on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BIOC?

1 brokers have issued 12-month price objectives for Biocept's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Biocept's stock price to reach $20.00 in the next year. This suggests a possible upside of 359.8% from the stock's current price.
View analysts' price targets for Biocept
or view top-rated stocks among Wall Street analysts.

Who are Biocept's key executives?

Biocept's management team includes the following people:
  • Mr. Michael W. Nall, CEO, Pres & Director (Age 58, Pay $739.58k)
  • Mr. Timothy C. Kennedy, CFO, COO & Corp. Sec. (Age 63, Pay $504.33k)
  • Mr. Michael Terry, Sr. VP of Corp. Devel. (Age 66, Pay $306.47k)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Pavel Tsinberg, Director of Technology Devel.
  • Mr. Michael W. Brown, Gen. Counsel and Compliance & Privacy Officer
  • Mr. David S. Moskowitz R.Ph., MBA, VP of Strategy & Corp. Communications
  • Ms. Brenda Tang, Sr. Director of Marketing
  • Mr. Gary Marchetti, Sr. Director of People & Culture/Facilities
  • Dr. Veena M. Singh, Sr. Medical Director (Age 46)

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Biocept's key competitors?

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.98%), Belvedere Trading LLC (0.56%), Hussman Strategic Advisors Inc. (0.54%), GSA Capital Partners LLP (0.29%) and Trexquant Investment LP (0.08%).
View institutional ownership trends for Biocept
.

Which major investors are buying Biocept stock?

BIOC stock was acquired by a variety of institutional investors in the last quarter, including Belvedere Trading LLC, Hussman Strategic Advisors Inc., Geode Capital Management LLC, GSA Capital Partners LLP, and Trexquant Investment LP.
View insider buying and selling activity for Biocept
or or view top insider-buying stocks.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $4.35.

How much money does Biocept make?

Biocept has a market capitalization of $58.30 million and generates $27.46 million in revenue each year.

How many employees does Biocept have?

Biocept employs 104 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

Where are Biocept's headquarters?

Biocept is headquartered at 5810 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.